Nifuroxazide Mitigates Angiogenesis in Ehlrich’s Solid Carcinoma: Molecular Docking, Bioinformatic and Experimental Studies on Inhibition of Il-6/Jak2/Stat3 Signaling

Nifuroxazide Mitigates Angiogenesis in Ehlrich’s Solid Carcinoma: Molecular Docking, Bioinformatic and Experimental Studies on Inhibition of Il-6/Jak2/Stat3 Signaling

Nifuroxazide is an antidiarrheal medication that has promising anticancer activity against diverse types of tumors. The present study tested the anticancer activity of nifuroxazide against Ehrlich’s mammary carcinoma grown in vivo. Furthermore, we investigated the effect of nifuroxazide on IL-6/jak2...

Full description

Bibliographic Details
Main Authors: Mohamed El-Sherbiny, Rehab M. El-Sayed, Mohamed A. Helal, Afaf T. Ibrahiem, Hoda S. Elmahdi, Mohamed Ahmed Eladl, Shymaa E. Bilay, Asma M. Alshahrani, Mona K. Tawfik, Ziad E. Hamed, Amany O. Mohamed, Sawsan A. Zaitone
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Molecules
Subjects:
angiogenesis
bioinformatics
Ehrlich’s solid tumors
molecular docking
IL-6/Jak2/STAT3 signaling
nifuroxazide
Online Access:https://www.mdpi.com/1420-3049/26/22/6858

Internet

https://www.mdpi.com/1420-3049/26/22/6858

Similar Items